25% Dextrose Infant Injection, Solution
NDC Package 51662-1213-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

25% Dextrose Infant injection is 25% Dextrose Injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co. Llc, Dba Health First, this product is identified by NDC 51662-1213 and is authorized under FDA application NDA019445.

Identification & Billing

NDC Package Code
51662-1213-1
Package Description
1 SYRINGE, PLASTIC in 1 CARTON / 10 mL in 1 SYRINGE, PLASTIC
Product Code
51662-1213
11-Digit Billing Format
51662121301
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
25% Dextrose Infant
Non-Proprietary Name
25% Dextrose Infant
Substance Name
Dextrose Monohydrate
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
DEXTROSE MONOHYDRATE 250 mg/mL
Usage Information
25% Dextrose Injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. Other drugs, such as epinephrine and glucagon, should be considered in patients unresponsive or intolerant to dextrose (glucose). Oral feeding of dextrose may be necessary in infants with frequently recurring hypoglycemic episodes or to prevent recurrences due to hyperinsulinemia.25% Dextrose Injection also provides a minimal source of carbohydrate calories.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co. Llc, Dba Health First
Product Type
Human Prescription Drug
FDA Application #
NDA019445
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-19-2018
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1213-1 identifies a specific commercial package of 1 syringe, plastic in 1 carton / 10 ml in 1 syringe, plastic of 25% Dextrose Infant, a human prescription drug labeled by Hf Acquisition Co. Llc, Dba Health First. This injection, solution is formulated for intravenous use and contains dextrose monohydrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co. Llc, Dba Health First on August 19, 2018. The current certification is valid through December 31, 2026.

How is this Hf Acquisition Co. Llc, Dba Health First product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662121301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1213-1
11-Digit CMS (5-4-2)
51662-1213-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.